Quick Answer
Viridian Therapeutics, Inc.DE reported Diluted EPS of $5.31 per share (loss) for fiscal year 2023.
Viridian Therapeutics, Inc.DE Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2023 | -$5.31 | -31.1% |
| 2022 | -$4.05 | +39.2% |
| 2021 | -$6.66 | +78.6% |
| 2020 | -$31.13 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | -$1.15 | -5.5% | -12.7% |
| June 30, 2024 | -$1.02 | +19.7% | -29.1% |
| March 31, 2024 | -$0.79 | +50.9% | +27.5% |
| September 30, 2023 | -$1.09 | -26.7% | +14.2% |
| June 30, 2023 | -$1.27 | -19.8% | +21.1% |
| March 31, 2023 | -$1.61 | -64.3% | -87.2% |
| September 30, 2022 | -$0.86 | +31.2% | +18.9% |
| June 30, 2022 | -$1.06 | +52.0% | -8.2% |
- Viridian Therapeutics, Inc.DE showed a decrease of -31.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2023 period, Viridian Therapeutics, Inc.DE’s diluted eps has grown by 82.9% (from $31.13 per share (loss) to $5.31 per share (loss)).
- The most recent figure is from Viridian Therapeutics, Inc.DE’s fiscal year 2023 report (Form 10-K), filed with the SEC on February 27, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: